CA-PROSIMO
30.11.2022 15:02:07 CET | Business Wire | Press release
Prosimo, the Application Experience Infrastructure company, announced that it is joining forces with Amazon Web Services (AWS) to provide complete end-to-end orchestration for the new AWS Verified Access service.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005237/en/
Prosimo is joining forces with Amazon Web Services (AWS) to provide complete end-to-end orchestration for the new AWS Verified Access service (Graphic: Business Wire)
Prosimo is working with AWS to allow enterprises to customize and deploy zero trust network access (ZTNA) rapidly while ensuring complete data and traffic control. Prosimo's platform simplifies the orchestration of the AWS Verified Access service and provides additional performance optimization using AWS backbone, intelligent routing, and application services. Enterprises can instantaneously access any of the latest cloud-native capabilities, like AWS Verified Access, without having to re-architect their existing clouds or worry about managing multiple environments. This approach enables enterprises to quickly develop, test and deploy secure, high-performing applications across any public or hybrid cloud environment.
"Cloud-forward organizations require a cloud-native ZTNA architecture - one that combines secure access with performance and posture to meet the challenges of modern applications in the cloud," said Ramesh Prabagaran, Co-founder and CEO of Prosimo. "Our deepening work with AWS allows us to deliver tightly coupled integrations rapidly that enable customers to simplify and streamline IT operations with fewer resources."
Why traditional ZTNA solutions fall short
Traditional ZTNA approaches take traffic to the vendor cloud-first to enforce policies and bring it back to the AWS Region close to the application. The model breaks a well-architected framework by not utilizing cloud-native services and optimized flows using AWS backbone and services such as AWS Transit Gateway, AWS Cloud WAN, AWS Global Accelerator, and AWS PrivateLink. This often leads to operational complexity, increasing risk, escalating costs, and negative impacts on performance.
Secure Access + Performance at Cloud Speed
Prosimo provides an end-to-end orchestration solution with advanced controls using these cloud-native services from AWS. The Prosimo Full Stack takes a comprehensive approach to help customers deploy AWS Verified Access and includes performance optimization, secure access, dynamic risk calculation, and orchestration of all ecosystem components, such as identity provider [IDP] integration, Domain Name Service [DNS], and connectivity, without any traffic leaving customers’ AWS environment. In addition to secure access, Prosimo can balance and optimize performance and costs per application basis.
One-click purchase and billing in AWS Marketplace
Prosimo solutions are available in AWS Marketplace and allow customers to seamlessly consume Prosimo solutions with one easy click of a button and consolidate billing.
Resources
- 2022 Gartner® Market Guide for Multicloud Networking Software
- Turbo Charge ZTNA with Prosimo and AWS [Technical Blog]
- AWS + Prosimo
- Prosimo Full Stack Cloud Transit
- Prosimo + AWS Cloud WAN
- Cloud Field Day: Simplifying Multi-Cloud Networking with Prosimo
Connect with Prosimo
About Prosimo
Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release
NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
